1 **TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional**

2 **motor neurons**

3 **Heeyoung An[1,2,7] , Hye-Lan Lee[3,4,7],** Doo-Wan Cho[5], Jinpyo Hong[6] , Hye Yeong Lee [3,4], Jung Moo Lee[1,2],

4 Junsung Woo[6], Jaekwang Lee[6], MinGu Park[1,2], Young-Su Yang[5], Su-Cheol Han[5]**, Yoon Ha[3,4*], C. Justin Lee[2,8*]**

5   1   KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro,

6   Seongbuk-gu, Seoul, 02841, Republic of Korea

7   2   Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon, 34126, Korea

8   3   Spine & Spinal Cord Institute, Department of Neurosurgery, College of Medicine, Yonsei University,

9   Seoul, Republic of Korea

10   4   Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea

11   5   Jeonbuk Branch Institute, Korea Institute of Toxicology, Jeongeup, 56212, South Korea

12   6   Center for Glia-Neuron Interaction, Korea Institute of Science and Technology (KIST), Seoul, 02792,

13   Korea

14   7   These authors contributed equally

15   8   Lead Contact

16

17 "*Correspondence: cjl@ibs.re.kr (C.J.L), hayoon@yuhs.ac (Y.H.) "

18

19 **Highlights**

20   TRANsCre-DIONE converts reactive astrocyte into neuron by over-expression of *Neurog2*

21   Reactive astrocytes are targeted using split-Cre under two promoters, *GFAP* and *Lcn2*

22   TRANsCre-DIONE reduces reactivity, replaces dead neurons and alleviates symptom of SCI

23   Transdifferentiated-neurons are GABA+ in the striatum and Isl1+ in the spinal cord

24

25

1   **SUMMARY**

2   In spinal cord injury (SCI), the scar-forming reactive astrocytes with upregulated GFAP proliferate

3   aberrantly near the injury site, allowing themselves as a prime target for transdifferentiation into

4   neurons to replenish dead neurons. However, the conventional use of *GFAP* promoter to target

5   reactive astrocytes has two inherent problems: inadvertent conversion of normal astrocytes and low

6   efficiency due to progressive weakening of promoter activity during transdifferentiation. Here, we

7   report that the scar-forming reactive astrocytes are selectively transdifferentiated into neurons with 87%

8   efficiency and 96% specificity via TRANsCre-DIONE, a combination of the split-Cre system under

9   two different promoters of *GFAP* and *Lcn2* and a Cre-loxP-dependent inversion and expression of

10   *Neurog2* under the strong *EF1α* promoter. After SCI, TRANsCre-DIONE caused transdifferentiation

11   into Isl1-positive motor neurons, reduced astrogliosis, enhanced regeneration in surrounding cells, and

12   a significant motor recovery. Our study proposes TRANsCre-DIONE as the next-generation

13   therapeutic approach for patients suffering from SCI.

14

15   **KEYWORDS**

16   Transdifferentiation, Direct reprogramming, Spinal cord injury, Glial scar, Reactive astrocyte,

17   Neuroregeneration, Functional recovery, TRANsCre-DIONE

1 **INTRODUCTION**

2   Spinal cord injury (SCI) induces irreversible neuronal death and glial scar formation, which results

3 in permanent motor and sensory dysfunction (Ahuja et al., 2017; Cregg et al., 2014; Su et al., 2014).

4 Although many attempts have been set forth to regenerate damaged spinal cord, currently doctors can

5 prescribe medications only to relieve pain to SCI patients. There is no drug or therapeutic tool to help

6 regenerate neurons and cause functional recovery, other than strenuous rehabilitation regimes

7 (Alizadeh et al., 2019; Assinck et al., 2017; Nagoshi and Okano, 2018). The much-hoped-for stem cell

8 therapy still has a long way to go in clinics due to its issues with low efficacy and safety. The safety

9 issues include tumor formation, immune rejection and unnecessary pain by reprogrammed neurons

10 forming improper neural connections (Abad et al., 2013; Yin et al., 2019). These serious risks are

11 majorly caused by transplantation of induced stem cells which still might have pluripotency (Li and

12 Chen, 2016).

13   To overcome the limitations of transplantation, the concept of transdifferentiation or direct

14 reprogramming of one type of differentiated resident cells into other cell types has been proposed (Li

15 and Chen, 2016; Xu et al., 2015). It has been reported that diverse cell types, including fibroblast,

16 microglia, and astrocyte can be transdifferentiated into neurons using various transcription factors

17 (Guo et al., 2014; Heinrich et al., 2010; Matsuda et al., 2019; Takahashi et al., 2007; Victor et al.,

18 2014). Among these cell types, the glial fibrillary acidic protein (GFAP)-positive astrocytes are known

19 as the most abundant cell type in the brain (Barres, 1991). Under normal conditions, astrocytes

20 provide various neurotrophic factors for neuronal growth and survival, regulate ionic homeostasis by

21 taking up potassium ions and glutamate, and engage in synaptic transmission and plasticity by

22 releasing gliotransmitters (De Pitta et al., 2011). However, under pathological conditions such as in

23 SCI, these normal astrocytes transform at the site of injury into reactive astrocytes and become

24 hypertrophied and proliferative, especially under a severe condition (Chun and Lee, 2018), to

25 eventually form a glial scar (Anderson et al., 2016; Burda and Sofroniew, 2014; Okada et al., 2018).

The severely reactive astrocytes over-express oxidizing enzymes such as MAO-B to cause oxidative stress and become highly toxic to neighboring neurons (Chun et al., 2018). Therefore, these proliferating and scar-forming severely reactive astrocytes can be a prime target for transdifferentiation into neurons to remove these toxic severely reactive astrocytes and replace dead neurons after injury.

GFAP promoter has been widely used to both target astrocytes and drive expression of transcription factors for transdifferentiation into neurons (Brulet et al., 2017; Guo et al., 2014; Heinrich et al., 2010; Mattugini et al., 2019; Su et al., 2014). Despite the universal application of the *GFAP* promoter (Brenner et al., 1994), the efficiency of transdifferentiation *in vivo* has been shown to be lower than 30% in a mouse model of spinal cord injury (Su et al., 2014). The low efficiency is probably due to most of the astrocytes being prematurely terminated of transdifferentiation by the reduced expression of a transcription factor under *GFAP* promoter as the *GFAP* promoter activity is downregulated by the conversion of astrocytes into neurons. Therefore, the use of *GFAP* promoter to drive the expression of a transcription factor in astrocytes for transdifferentiation may not be optimal. More importantly, using solely *GFAP* promoter is not an ideal strategy for targeting reactive astrocytes because GFAP is also expressed in some neural progenitor cells as well as normal astrocytes (Liu et al., 2010; Park et al., 2018). This raises a possibility that some neural progenitor cells and normal astrocytes might unintentionally transdifferentiate into neuron-like cells. In fact, although a recent study reported a high transdifferentiation efficiency of 80% with only *GFAP* promoter to target reactive astrocytes in the brain of Alzheimer's disease and Huntington's disease mouse models (Guo et al., 2014; Wu et al., 2020), the apparent high efficiency might have been over-estimated by an undesirable targeting of neural progenitor cells and normal astrocytes. Therefore, to target only reactive astrocytes while sparing neural progenitor cells and normal astrocytes, it is essential to utilize one or more reactive-astrocyte-specific promoters such as *Lcn2* (Bi et al., 2013) and *iNOS* (Walsh et al., 2004; Zhao et al., 1998) in combination with *GFAP* promoter. Moreover, to continuously drive the expression of a transcription factor even in the transdifferentiated state, it is necessary to utilize a strong universal

1   promoter, whose activity is maintained high regardless of the cell types. To prevent an inadvertent

2   expression of a transcription factor in untargeted cells under a strong universal promoter, the gene of

3   transcription factor should remain in an inactive form, whereas it should be switched to an active form

4   at once in targeted cells. To address these requirements, we have utilized the split-Cre system

5   (Hirrlinger et al., 2009a; Hirrlinger et al., 2009b) under two separate promoters for reactive astrocytes,

6   which will switch on a gene of transcription factor by Cre/DIO (double floxed inversed orientation)-

7   dependent inversion (Tronche et al., 2002). The inverted gene of transcription factor is then

8   continuously expressed as it is driven by a strong universal promoter *EF1α* (Wang et al., 2017).

9   To transdifferentiate reactive astrocytes into motor neurons in spinal cord injury model, we have

10   considered various transcription factors that have been used to transdifferentiate astrocytes to neurons.

11   To transdifferentiate fibroblasts into neurons directly, achaete-scute family bHLH transcription factor

12   1 (A*SCL1)* has been included in combination with other transcription factors such as *Sox2, Oct4*, and

13   *Dlx1* (Liu et al., 2016). To transdifferentiate astrocytes into neurons, *Neurog2* and its downstream

14   factor, *NeuroD1* (Seo et al., 2007), have been sequentially introduced as a single transcription factor

15   *in vitro* (Berninger et al., 2007; Heinrich et al., 2010) and *in vivo* (Guo et al., 2014; Hu et al., 2019).

16   To transdifferentiate fibroblasts into the Isl1-positive motor neurons, *Neurog2* has been included in

17   combinations with other transcription factors (Liu et al., 2016; Tang et al., 2017). However, *Neurog2*

18   has not been used for transdifferentiation of reactive astrocytes into motor neurons in spinal cord

19   injury model. On the other hand, *NeuroD1* has been used frequently for transdifferentiation of

20   astrocytes into glutamatergic neurons in combination with other transcription factors (Wang et al.,

21   2016), but rarely for transdifferentiation into motor neurons in combination with five other

22   transcription factors (Wang et al., 2016). Only *Sox2* in combination with other factors has been used

23   for transdifferentiation of astrocytes to neurons in spinal cord injury model (Wang et al., 2016).

24   However, the study did not report any functional recovery after injury (Wang et al., 2016). Based on

25   these previous findings, we selected *Neurog2* as an optimal single transcription factor for

1   transdifferentiation of reactive astrocytes into motor neurons. In this study, we employ **TRANsCre-**

2   **DIONE** (**T**ransdifferentiation of **R**eactive **A**strocytes to **N**eurons by **s**plit-**Cre** using GFAP and Lcn2

3   or iNOS turning on of **DIO**-**N**eurogenin2 under **E**F1a promoter), a unique combination of split-Cre

4   under two separate promoters for reactive astrocytes and Cre/DIO-dependent inversion of *Neurog2*

5   under a strong universal promoter of *EF1α* to transdifferentiate scar-forming reactive astrocytes into

6   Isl1-positive motor neurons in hope for functional recovery in mouse model of spinal cord injury.

7

8

1 **RESULT**

2 **The genetic strategy of transdifferentiation in the brain of a mouse and non-human primate**

3 The scar-forming reactive astrocytes exhibit upregulation of *GFAP* and neuroinflammation-related

4 genes such as lipocalin2 (*Lcn2*) and induced nitric oxide synthase (*iNOS*) (Walsh et al., 2004; Zhao et

5 al., 1998). To express the transcription factor in reactive astrocytes more specifically, we introduced

6 split-Cre which is the split-form of the whole improved Cre (iCre), divided into two parts composed

7 of N-terminal part of the iCre (Ncre) and C-terminal part of the iCre (Ccre) (Hirrlinger et al., 2009a;

8 Hirrlinger et al., 2009b), under two different promoters. To confirm the induction of the gene products

9 of *Lcn2* and *iNOS* in the reactive astrocytes, we immunostained the injured tissues with antibodies

10 against Lcn2 and iNOS. To apply the traumatic injury to the brain of the mouse and monkey, the 32-

11 gauge and 23-gauge needle was used for virus injection, respectively (Figure 1A). To induce an injury

12 to the mouse spinal cord, a compression injury was introduced by self-closing forceps for 3 s followed

13 by virus injections into the two points next to the injury site (Figure 1A). The GFAP signal increased

14 in both mouse and monkey when the tissues were injured. Lcn2 was induced in the injured mouse

15 brain and spinal cord (Figure 1B) while only the iNOS signal was induced without the Lcn2 signal in

16 the injured monkey's brain tissues (Figure 1B). Lcn2 and iNOS were never observed in the uninjured

17 tissues (Figure S1). Along with these results, for gene expression in reactive astrocytes specifically,

18 *Lcn2* was used with *GFAP* as promoters of split-Cre in the mouse brain and spinal cord, and *iNOS* and

19 *GFAP* were used for the promoters of split-Cre in the monkey's brain (Figure 1C). All genes were

20 cloned and packaged into Adeno-associated virus (AAV) for broad and robust gene expression in the

21 brain and spinal cord. *Neurog2* was expressed only in reactive astrocytes because both sides of the

22 split-Cre can be expressed only in reactive astrocytes to make a functional Cre. Thus, we used

23 TRANsCre-DIONE, composed of pAAV-EF1α::DIO-Neurog2-IRES-GFP (DIO-Neurog2) with

24 pAAV-Lcn2::NCre and pAAV-GFAP::CCre in the mouse and pAAV-iNOS::CCre and pAAV-

25 GFAP::NCre in the monkey brain (Figure 1C). In addition, GFP fluorescence (under *IRES*; Internal

7

1   Ribosome Entry Site) was used as a reporter for easy monitoring of TRANsCre-DIONE-containing

2   cells, *i.e.* untransdifferentiated reactive astrocytes or transdifferentiated neurons. The split-Cre system

3   did not show any leakiness in the NCre or CCre only condition (Figure S2). With these results, we

4   designed TRANsCre-DIONE using *Lcn2* and *GFAP* promoters of split-Cre for mouse and *iNOS* and

5   *GFAP* promoters of split-Cre for monkey to express *Neurog2* in reactive astrocytes specifically.

6   **Transdifferentiation of reactive astrocytes into functional neurons in the mouse brain**

7   To examine whether it is possible that the reactive astrocytes can specifically transdifferentiate into

8   neurons with one transcription factor *in vivo* and to confirm the efficiency of transdifferentiation, we

9   injected TRANsCre-DIONE, a mixture of packaged AAV (1:1:1) for control group (AAV- EF1α-DIO-

10   EGFP with AAV-Lcn2-NCre and AAV-GFAP-CCre) and Neurog2 group (AAV-EF1α-DIO-Neurog2-

11   IRES-EGFP with AAV-Lcn2-NCre and AAV-GFAP-CCre) bilaterally into the mouse striatum (ML

12   1.85mm, AP 0.5mm, DV -3.0mm). The mice were sacrificed 3 weeks after injection (Figure 2A). We

13   immunostained the tissues with antibodies against GFAP and NeuN for distinguishing the cell types of

14   GFP expressing cells. The efficiency of transdifferentiation was calculated by counting the number of

15   GFAP and NeuN positive cells in GFP expressing cells. Most of the GFP expressing cells (62%, 84

16   out of 135 cells) were NeuN positive in the Neurog2 group while only 1% (1 out of 93 cells) of GFP

17   expressing cells were NeuN positive in the control group (Figure 2B and 2C). Most of the GFP

18   expressing cells (89%, 83 out of 93 cells) in the control group remained GFAP-positive astrocytes

19   while 28% (39 out of 135 cells) of the GFP expressing cells in Neurog2 group were GFAP positive

20   (Figure 2B and 2C). These results demonstrate that GFAP positive reactive astrocytes

21   transdifferentiate into neurons in the mouse striatum by expressing *Neurog2* solely.

22   Striatal neurons are composed of 100% GABA expressing neurons with 95% medium-spiny neurons

23   expressing both GABA and DARPP32 and 5% of the aspiny GABAergic interneurons (Tepper et al.,

24   2010). In contrast, it has been reported that the transdifferentiated neurons from cultured astrocytes

25   upon over-expression of *Neurog2* were mostly glutamatergic neurons (Heinrich et al., 2010), raising a

8

1   strong possibility that the transdifferentiated neurons in the striatum are glutamatergic, rather than

2   GABAergic. To determine whether the transdifferentiated neurons in the striatum are GABAergic, we

3   performed double-immunostaining with antibodies against NeuN and GABA (Figure 2D). By surprise,

4   we found that 83.64 % of the NeuN+ GFP-expressing cells were GABA+ (Figure 2E), indicating that

5   the majority of the transdifferentiated neurons were GABAergic in the striatum. These results suggest

6   that over-expression of *Neurog2* causes transdifferentiation into GABAergic neurons in the specific

7   environment surrounded by GABAergic neurons.

8   To test the functional property of transdifferentiated neurons from reactive astrocytes by forced

9   *Neurog2* expression, we performed whole-cell patch-clamp recording in the infected cells. GFP

10   expressing cells (Figure 2F, inset) in the control group showed a large and linear passive conductance

11   current (Figure 2F, upper panel), which is a unique physiological property of astrocytes in the striatum

12   (Figure 2F). Contrary to the control group, GFP expressing cells (Figure 2F, inset) from the Neurog2

13   group showed robust action potential firing (Figure 2G, upper panel) by the current-clamp recording

14   with whole-cell patch clamp *ex vivo*. The spontaneous excitatory postsynaptic currents (EPSCs)

15   (Figure 2G, inset) and large sodium and potassium currents were also observed (Figure S4), indicating

16   the maturity of the transdifferentiated neurons (Figure 2G). The similar morphological change and

17   action potential firing were observed within 14 days after transducing *Neurog2* in culture (Figure

18   S3A-C). These results demonstrate that reactive astrocytes transdifferentiate into functional neurons

19   by expressing solely *Neurog2* in reactive astrocytes.

20   **Transdifferentiation of reactive astrocytes into functional neurons in the monkey's brain**

21   To investigate if transdifferentiation occurs in the brain of non-human primates, we injected

22   TRANsCre-DIONE into the putamen of cynomolgus monkeys *(Macaca fascularis)* as previously

23   described (An et al., 2016) and harvested the brain tissues after four weeks (Figure 3A). As mentioned

24   above (Figure 1D), *iNOS* was used as a promoter instead of *Lcn2* with *GFAP* for transducing *Neurog2*

25   into reactive astrocytes in the monkey's brain (Figure 3A). Harvested brain tissues were

9

1   immunostained with antibodies against GFAP and NeuN as well (Figure 3B). GFP-expressing cells

2   rarely colocalized with NeuN in the control group, while considerable GFP-expressing cells were

3   NeuN positive in the Neurog2 group (Figure 3B). These results demonstrate that the reactive

4   astrocytes in the monkey's brain also transdifferentiate into NeuN-positive neurons by expressing

5   *Neurog2*. To investigate whether the infected cells completely transdifferentiate into neurons or not,

6   we generated a scatter plot of GFAP intensity *versus* NeuN intensity of all GFP-expressing cells.

7   GFP-expressing cells in the control group (Figure 3C, blue dots) show low NeuN and high GFAP

8   intensity forming a distinct cluster in the left upper quadrant (G+/N-) (Figure 3C). GFP-expressing

9   cells in the Neurog2 group (Figure 3C, pink dots) switched to the right direction in general, indicating

10   that the cells express stronger NeuN signal than in the control group. The cells in the right lower

11   quadrant (G-/N+) might be completely transdifferentiated into neurons, whereas the cells in the right

12   upper quadrant (G+/N+) are in the transition from astrocytes to neurons (Figure 3C). In the Neurog2

13   group, GFAP-negative (G-) cells occupied almost half of the GFP-expressing cells. Contrary to the

14   Neurog2 group, almost all the GFP-expressing cells in the control group were GFAP-positive (G+)

15   (Figure 3D). While GFP-expressing cells exhibited strong astrocyte properties with high GFAP

16   intensity and low NeuN intensity in the control group (Figure 3E), the cells in the Neurog2 group

17   exhibited much more neuron-like properties with increased NeuN and decreased GFAP intensities,

18   reaching to the similar level of intensity to each other (Figure 3F). In other words, GFP-expressing

19   cells in the Neurog2 group expressed higher NeuN (Figure 3G) and lower GFAP intensity than those

20   of the control group (Figure 3F). Taken together, the reactive astrocytes transdifferentiated into more

21   neuron-like cells in the brain of non-human primates by sole expression of *Neurog2*.

22

23   **Transdifferentiation of scar-forming reactive astrocytes into functional neurons in the spinal**

24   **cord injury mouse model**

25   To investigate whether the transdifferentiated neurons from reactive astrocytes can ameliorate the

10

1   motor impairment caused by spinal cord injury, we generated the spinal cord injury mouse model with

2   forceps compressing of spinal cord at Thoracic vertebra (T10) (Figure 4B) and injected TRANsCre-

3   DIONE (AAV-EF1α-DIO-Neurog2-IRES-EGFP with AAV-Lcn2-NCre and AAV-GFAP-CCre) into

4   1mm above and below the injury site two weeks after injury (Figure 4A and 4B). Starting from the

5   time of injury, every week we measured the Basso Mouse Scale (BMS) that represents locomotion

6   defects during recovery. SCI mice were scored from zero to nine based on each mouse's ability to

7   move its lower body. The impaired movement was significantly ameliorated to an average BMS score

8   of 3.88 at   8 week in the SCI/Neurog2 group, while the mice in SCI/Ctrl and SCI/PBS group were

9   scored below an average of 1 (Figure 4C). These results indicate that TRANsCre-DIONE can

10 alleviate the motor impairment of SCI mouse model. To investigate whether the transdifferentiated

11 cells display functional properties of neurons, GFP-expressing cell (inset, Figure 4D) in the Neurog2

12 group was recorded by whole-cell patch clamp. GFP-expressing cell showed robust action potential

13 firing (Figure 4D), large sodium currents (Figure 4E), and numerous spontaneous EPSCs (Figure 4F).

14 Taken together, TRANsCre-DIONE causes an improvement of motor behavior and

15 transdifferentiation into functional neurons in SCI.

16

17 **Tissue recovery in SCI via transdifferentiation of scar-forming reactive astrocytes into neurons**

18   To test whether over-expression of *Neurog2* in reactive astrocytes causes tissue recovery, we

19 performed Erich-Chrome (EC) staining with the spinal cord tissues to measure the myelinated, gray

20 matter and total areas (Figure 5A). Although the tissues were severely shrunken and damaged in

21 SCI/PBS group and SCI/Ctrl group, tissues in Neurog2 group were recovered almost to the sham

22 group (Figure 5A). The gray matter, myelinated and total areas were decreased in SCI/PBS (27.95%,

23 28.77%, 28.39%) and SCI/Ctrl (37.74%, 12.69%, 26.01%) groups compared to the sham group, and

24 the areas were significantly increased in SCI/Neurog2 group (66.37%, 49.51%, 57.45%) (Figure 5B).

25 To explore whether the damaged axon and dendrites were recovered in the injured spinal cord, we

1 immunostained the longitudinal spinal cord sections with an antibody against MAP2. Although the

2 MAP2 signal was almost disappeared around the injury site in SCI/PBS and SCI/Ctrl groups, it was

3 remarkably recovered in SCI/Neurog2 group (Figure 5C). These results demonstrate that myelinated

4 axon and the damaged tissue structure might be restored via TRANsCre-DIONE.

5 **Transdifferentiation of reactive astrocytes into motor neurons in SCI**

6 Isl1 is necessary for differentiating most of the subtypes of motor neurons such as VChAT+, ChAT+,

7 CHT+ neurons, and Isl1-expressing cholinergic motor neurons are major cell types in the spinal cord

8 (Cho et al., 2014). To examine whether over-expression of *Neurog2* induces transdifferentiation of

9 reactive astrocytes into specific neurons, we immunostained the spinal cord tissues with antibodies

10 against Isl1, the key molecular marker for motor neuron (Tang et al., 2017), and other neuronal

11 markers such as MAP2 and NeuN. MAP2 signal was disappeared in SCI/PBS and SCI/Ctrl groups

12 and significantly restored in SCI/Neurog2 group (Figure 6A and 6C). MAP2 signal in GFP-expressing

13 cells was also significantly increased in SCI/Neurog2 group compared to SCI/Ctrl group (Figure 6A

14 and Figure6D). 97.32% of the GFP-expressing cells were MAP2 positive in SCI/Neurog2 group,

15 while 98.88% of the GFP-expressing cells were GFAP positive in SCI/Ctrl group. These results

16 indicate that   the most of the GFP expressing cells were transdifferentiated into MAP2+ neurons via

17 expression of *Neurog2* in SCI.

18 NeuN signal was also disappeared in SCI/PBS and SCI/Ctrl groups and significantly recovered in

19 SCI/Neurog2 group (Figure 6B and Figure 6H). NeuN signal in GFP-expressing cells was also

20 significantly increased in SCI/Neurog2 group compared to SCI/Ctrl group (Figure 6B and Figure 6I).

21 To determine the transdifferentiation efficiency and specificity, we performed detailed analysis of

22 GFP-expressing cells by plotting NeuN versus GFAP (Figure S4B and S4C). We found that 87% (67

23 out of 77 cells) of GFP-expressing cells were NeuN positive in SCI/Neurog2 group, while only 3.92%

24 (4 out of 102 cells) were NeuN positive in SCI/Ctrl group (Figure 6F). Finally, the Isl1 signal was

25 disappeared in SCI/PBS and SCI/Ctrl groups and significantly increased in SCI/Neurog2 group

1   (Figure 6B and 6J). The Isl1 signal in GFP-expressing cells was also significantly increased in

2   SCI/Neurog2 group compared to SCI/Ctrl group (Figure 6B and Figure 6K). The percentage of

3   Isl1+/GFP+ motor neurons in total Isl1+ motor neurons was significantly increased in SCI/Neurog2

4   group, while all the Isl1+ motor neurons were GFP- in SCI/Ctrl group (Figure 6B and Figure 6L).

5   These results indicate that reactive astrocytes transdifferentiated into Isl1+ motor neurons in the

6   injured spinal cord by over-expression of *Neurog2*. To explore whether over-expression of *Neurog2* in

7   reactive astrocytes affects the reactivity of astrocytes, we immunostained the tissues with the antibody

8   against GFAP. While the GFAP signal was increased in SCI/PBS and SCI/Ctrl groups, GFAP was

9   significantly decreased in SCI/Neurog2 group (Figure 6A, 6B and 6G). Taken together, TRANsCre-

10   DIONE induces transdifferentiation of reactive astrocytes into motor neurons and attenuates the

11   reactivity of astrocytes in the injured spinal cord.

12

13   **Transdifferentiated neurons are mostly originated from non-proliferating cells**

14   To investigate whether the transdifferentiated neurons are derived from proliferating cells, we

15   performed labeling with Bromodeoxyuridine (BrdU) which is incorporated into DNA during cell

16   proliferation (Russo et al., 1984). BrdU was administered once a day for one week to the SCI mice

17   before they were sacrificed at the time of 3-week (Figure S5B) and 8-week (Figure7B). For detecting

18   BrdU signals in the specific cell types from GFP-expressing cells, we double-stained the tissues with

19   antibodies against GFAP or NeuN or MBP (myelination binding protein), the cell markers of astrocyte,

20   neuron and oligodendrocyte, respectively (Figure 7A and Figure S5A). In SCI/Ctrl group, only 12.06%

21   of the GFP+ cells and 9.60% of the GFP+/GFAP+ cells were labeled with BrdU, while most of the

22   GFP- cells were labeled with BrdU (87.90%, Figure 7C). Similarly, in SCI/Neurog2 group, only 5.90%

23   of the GFP+ cells and 1.18% of the GFP+/GFAP+ cells were labeled with BrdU, while almost all of

24   the GFP- cells were labeled with BrdU (94.09%, Figure 7C). These results indicate that most of the

25   GFP+ cells are not proliferating in the late stage (Figure 7C), as well as in the early stage of

1   transdifferentiation (Figure S5C). Double-labeling with BrdU and NeuN resulted in BrdU labeling of

2   only 10.36% of the GFP+ cells and 0.39% of the GFP+/NeuN+ cells in SCI/Ctrl group. Similarly,

3   BrdU labeled only 9.82% of the GFP+ cells and 9.62% of the GFP+/NeuN+ cells in SCI/Neurog2

4   group (Figure 7D). In contrast, most of the GFP- cells in SCI/Ctrl group (89%) and in SCI/Neurog2

5   group (85%) were labeled with BrdU (Figure 7D). These results indicate that most of the

6   transdifferentiated GFP+/NeuN+ cells are not proliferating in the late stage (Figure 7A and 7D), as

7   well as in the early stage of the transdifferentiation (Figure S5D). There were no GFP+/MBP+ cells in

8   both SCI/Ctrl and SCI/Neurog2 groups, indicating that oligodendrocytes were not transdifferentiating

9   into neurons (Figure 7E). Taken together, these results demonstrate that GFP+ transdifferentiated

10   neurons are mostly originated from BrdU negative non-proliferating cells in the early stage as well as

11   in the late stage of transdifferentiation.

12   To investigate whether the reduction of reactive astrocytes influences the proliferation of surrounding

13   cells (BrdU+/GFP-) near the transdifferentiated neurons, we assessed the proportion of BrdU+ cells in

14   each cell type (GFAP+, NeuN+, MBP+) among the surrounding GFP- cells (Table 1). We found that

15   the proportion of proliferating astrocytes near the transdifferentiated cells (GFP-/BrdU+/GFAP+) were

16   decreased from 9.62% (SCI/Ctrl) to 4.55% (SCI/Neurog2) in the early stage (3 week, Figure S5A),

17   from 12.50% (SCI/Ctrl) to 10.20% (SCI/Neurog2) in the late stage (8 week, Figure 7A). In contrast,

18   the proportion of GFP-/BrdU+/NeuN+ cells was increased from 0.00% (SCI/Ctrl) to 4.49%

19   (SCI/Neurog2) in the early stage (3 week, Figure S5A), from 1.93% to 9.80% in the late stage of

20   transdifferentiation (8 week, Figure 7A). Consistently, the proportion of GFP-/BrdU+/MBP+ cells

21   was increased from 9.13% (SCI/Ctrl) to 12.03% (SCI/Neurog2) in the early stage (3 week, Figure

22   S5A), from 1.33% to 11.94% in the late stage of transdifferentiation (8 week, Figure 7A). Taken

23   together, these results implicate that the regeneration of neighboring neurons (GFP-/BrdU+/NeuN+)

24   and oligodendrocytes (GFP-/BrdU+/MBP+) was enhanced when the astrocytic reactivity was

25   decreased by TRANsCre-DIONE in SCI/Neurog2 group in both early and late stages.

26

14

1   **DISCUSSION**

2   In this study, we have developed and characterized a novel molecular tool set, TRANsCre-DIONE,

3   which is highly effective (62% in mouse striatum, 87% in SCI) in replacing dead neurons in severe

4   injury conditions (Figure S6). The highlights of our study are that 1) TRANsCre-DIONE converts

5   reactive astrocytes into neurons by a sole over-expression of *Neurog2*, 2) reactive astrocytes are

6   specifically targeted using split-Cre under two promoters, *GFAP* and *Lcn2* in mouse and *GFAP* and

7   *iNOS* in monkey, 3) TRANsCre-DIONE reduces astrogliosis, replaces dead neurons and alleviates

8   symptoms of SCI, and 4) the transdifferentiated-neurons are GABA+ medium spiny neurons in the

9   striatum and Isl1+ motor neurons in the spinal cord. TRANsCre-DIONE shows an excellent

10   therapeutic potential in human as the combination of *GFAP* and *iNOS* was highly effective in the

11   striatum of non-human primate. TRANsCre-DIONE not only induced direct reprograming of the

12   infected cells but also caused an indirect enhancement of regeneration in neighboring cells, possibly

13   due to removing toxic reactive astrocytes.

14   In our recent studies, we have newly defined 'reactive' astrocytes as the astrocytes which respond to

15   damaging stimulations such as traumatic brain injury or toxic protein aggregates to turn on the MAO-

16   B-dependent GABA synthetic pathway as a consequence of degradation of toxic materials (Chun et al.,

17   2018; Chun and Lee, 2018). These 'reactive' astrocytes are known to be detrimental to neighboring

18   neurons and can be easily distinguished from 'active' astrocytes, which are known to be beneficial,

19   are present in conditions of enriched environment, and show an enhanced expression of proBDNF

20   with no GABA (Chun et al., 2018; Chun and Lee, 2018). Although the active and reactive astrocytes

21   can be easily distinguished by the two markers, proBDNF and GABA, it is not very easy to

22   distinguish them by the morphology, because both the active and reactive astrocytes show hypertrophy,

23   which is simply an increased level of GFAP expression. In other words, it is very difficult to

24   distinguish between beneficial active astrocytes and detrimental reactive astrocytes using GFAP alone.

25   By utilizing the reactive-astrocyte-specific inducible genes such as *Lcn2* and *iNOS* for promoters of

15

1   split-Cre in combination with *GFAP* promoter, we have overcome the limitations of solely using

2   *GFAP* promoter and succeeded in specifically targeting reactive astrocytes while sparing active and

3   normal astrocytes. Because Lcn2 and iNOS were never observed in the uninjured tissues and they

4   were induced only upon injury (Figure S1), we interpret the presence of the reporter GFP of

5   TRANsCre-DIONE as a direct representation of reactive astrocytes. We have observed that

6   TRANsCre-DIONE shows extremely high specificity for reactive astrocytes, targeting over 90.21% of

7   reactive astrocytes in the injured mouse striatum (Figure 2C), 93.13% in the injured monkey striatum

8   (Figure 3C), and 98.48% in SCI (Figure 6F). It is worth highlighting the near complete specificity of

9   the combination of *iNOS* and *GFAP* promoters in the monkey striatum. Such complete specificity is

10   most likely due to the specificity of iNOS for reactive astrocytes in non-human primate. These results

11   raise a promising therapeutic potential for an immediate clinical application of TRANsCre-DIONE in

12   injured human brain.

13   The specificity towards reactive astrocytes or neurons can be estimated by calculating the proportion

14   of GFAP+/GFP+ or NeuN+/GFP+ cells in total GFP+ cells in Ctrl group. In other words, the

15   specificity towards NeuN+ neurons in Ctrl group represents the leakiness of TRANsCre-DIONE

16   towards resident neurons. In the Ctrl group, we observed that only 1 out of 93 (1.07%) GFP+ cells

17   was NeuN+ in the mouse striatum (Figure 2C), 1 out of 98 (1.03%) GFP+ cells was NeuN+ in the

18   monkey's striatum (Figure 3C), and 4 out of 102 (3.92%) GFP+ cells was NeuN+ in the mouse spinal

19   cord (Figure 6F). These results indicate that TRANsCre-DIONE shows virtually no leakiness towards

20   resident neurons. In contrast, previously reported molecular tools display a significant degree of

21   leakiness towards resident neurons. Having a significant leakiness is problematic because it leads to

22   an inadvertent over-estimation of the efficiency of transdifferentiation. For example, in a recent study

23   using GFAP::Cre for selective expression of two transcription factors, *NeuroD1* and *Dlx2*, authors

24   reported that 10% of infected cells were NeuN+ in control condition (Wu et al., 2020): the efficiency

25   of transdifferentiation was 80% in the striatum of R6/2 Huntington disease mouse model. If at least 10%

26   of the targeted cells were already neurons, the reported transdifferentiation efficiency must have been

1　over-estimated. In another study using only GFAP promoter to target reactive astrocytes with

2　retroviral GFAP::NeuroD1-IRES-GFP, the transdifferentiation efficiency was reported to be over 80%

3　(Guo et al., 2014): this efficiency value might have been over-estimated due to a leakiness.

4　Unfortunately, the authors did not report a corresponding value for leakiness. Because TRANsCre-

5　DIONE shows virtually no leakiness towards neurons, our estimation of transdifferentiation efficiency

6　at 62% in the mouse striatum and 87% in SCI (Figure 6F) is considered to be fairly accurate with less

7　likelihood of over-estimation. Therefore, the performance of TRANsCre-DIONE in specificity as well

8　as in efficiency of transdifferentiation is unprecedentedly high.

9　The high transdifferentiation efficiency of TRANsCre-DIONE can be attributed to the use of DIO

10　system (Tronche et al., 2002) in combination with the strong *EF1α* promoter (Wang et al., 2017).

11　Unlike other previously reported molecular tools utilizing a simple *GFAP* promoter to drive an

12　expression of transcription factors (Guo et al., 2014; Su et al., 2014; Wu et al., 2020), this unique

13　combination ensures a sustained expression of *Neurog2* in the targeted reactive astrocytes even in the

14　transitional and transdifferentiated state. The net effect is that the transdifferentiation efficiency is

15　sustained high throughout the lifetime of transdifferentiated neurons. Furthermore, our approach of

16　*EF1α*-driven *DIO-Neurog2* system safely prevents an inadvertent expression of *Neurog2* in untargeted

17　cells even under the strong universal promoter, *EF1α*. This safety feature ensures no inadvertent

18　expression of *Neurog2* in untargeted normal astrocytes or other cell types. The net effect of this safety

19　feature is manifested as the virtually zero leakiness and high specificity of TRANsCre-DIONE.

20　Our study reveals that the sole use of the transcription factor, *Neurog2* is an excellent choice for

21　transdifferentiation of reactive astrocytes into neurons. We found that *Neurog2* alone is capable of

22　transdifferentiating reactive astrocytes - in cortical astrocyte culture, mouse and monkey striatum, and

23　mouse spinal cord - into neurons without a need for additional transcription factors. This is in great

24　contrast to the previous studies in which multiple transcription factors - in combination of *NeuroD1*

25　with *DLX2* (Wu, 2020), *Neurog2* with *SOX11* and *Lhx3* (Liu et al., 2016) and *BRN2* with *MYT1L,* and

1   *FEZF2* (Miskinyte et al., 2017) - have been utilized. Use of only one transcription factor provides an

2   important advantage in that, one can minimize the number of viral vectors and genes of interest to

3   deliver to the site of injury. More importantly, *Neurog2* possesses a chameleon-like property that

4   allows transdifferentiation of reactive astrocytes into various neuronal types depending on the

5   surrounding environment and region of the injury site. It has been shown that *Neurog2* can

6   transdifferentiate cultured astrocytes into glutamatergic neurons (Heinrich et al., 2010). It has been

7   also shown that *Neurog2* can transdifferentiate astrocytes into glutamatergic neurons or GABAergic

8   neurons *in vivo* in cortex, cerebellum, and spinal cord, although the majority was glutamatergic (Hu et

9   al., 2019). However, the transdifferentiation efficiency was less than 10% probably due to the use of

10   *GFAP* promoter alone to drive *Neurog2* expression (Hu et al., 2019). We have shown that *Neurog2*

11   under TRANsCre-DIONE can transdifferentiate reactive astrocytes into GABA+ medium spiny

12   neurons at high rate (83.64 %) in the mouse striatum (Figure 2D-E). In SCI, *Neurog2* was capable of

13   transdifferentiating reactive astrocytes into isl1+ cholinergic motor neurons (Figure 6K). These results

14   imply that the same transcription factor *Neurog2* can cause a transdifferentiation of the target cells

15   into different type of neurons and that the environmental factors strongly influence the fate of the

16   *Neurog2*–expressing transdifferentiating cells. How is this possible for *Neurog2*? As an upstream

17   master switch gene, *Neurog2* is known to induce sequential expression of other neurogenesis-related

18   downstream transcription factors such as *NeuroD1, NeuroD4, Hes6,* and *MyT1* (Seo et al., 2007).

19   Thus, *Neurog2* has a potential to induce transdifferentiation into diverse types of neurons by turning

20   on a specific switch depending on the niche of the residential brain regions. Unlike *Neurog2*,

21   *NeuroD1* appears to transdifferentiate astrocytes into mostly glutamatergic neurons in hippocampus

22   (Roybon et al., 2015; Wu et al., 2020) when it is used solely. *NeuroD1* appears to require other

23   transcription factors such as *DLX2* in combination to transdifferentiate into other type of neurons

24   other than glutamatergic neurons (Liu et al., 2020; Wu, 2020). In support of this idea, it has been

25   recently demonstrated that a gene-silencing of *PTBP1* induces transdifferentiation of Müller glia to

26   retinal ganglion cells in the retina, whereas it induces transdifferentiation of astrocytes into

1   dopaminergic neurons in the striatum without additional factors (Zhou et al., 2020). Interestingly,

2   authors found that there was no significant change in the level of *NeuroD1* in the transdifferentiated

3   retinal ganglion cells or dopaminergic neurons in the striatum, indicating that *NeuroD1* may not be the

4   downstream transcription factor of *PTBP1*-gene-silencing. It will be interesting to test whether

5   *Neurog2* is the downstream transcription factor of *PTBP1*-gene-silencing. Taken together, *Neurog2*

6   shows several advantages over *NeuroD1* and can be considered as the most optimal transcription

7   factor for transdifferentiation of reactive astrocytes into various types of neurons.

8   In this study, we have achieved multiple goals using TRANsCre-DIONE: elimination of detrimental

9   reactive astrocytes, replacement of dead neurons, and alleviation of motor symptoms in SCI model. It

10   has been proposed that the "scar-forming reactive astrocytes" (defined as "severe reactive astrocytes"

11   in our study) in SCI inhibit axon regeneration under the chronic pathological condition, while

12   "reactive astrocytes" (defined as "mild reactive astrocytes" in our study) serve protective roles in

13   acute pathological condition (Kijima et al., 2019). According to this proposed model, the "reactive

14   astrocytes" can be transformed into normal astrocytes or scar-forming reactive astrocytes by the

15   surrounding environment in the spinal cord (Okada et al., 2018). Thus, we focused on the effect of

16   eliminating the detrimental scar-forming reactive astrocytes to provide a niche for axon regeneration.

17   Consistence with the proposed model, we observed both a significant decrease in GFAP signal in

18   SCI/Neurog2 group, indicating a relief from astrocytic reactivity and a significant increase in MAP2

19   signal, indicating an enhanced axon regeneration. In addition, TRANsCre-DIONE synergistically

20   increased appearance of the BrdU+ proliferating cells that were GFP- (Table 1), indicating an

21   enhanced regeneration in the surrounding cells. Such unexpected synergistic effects by removing the

22   detrimental reactive astrocytes imply a pro-regenerative effect of TRANsCre-DIONE.

23   In conclusion, TRANsCre-DIONE proves to be highly efficient and specific in transdifferentiating

24   reactive astrocytes to appropriate neurons in different regions of the injured brain. The complete

25   absence of tumorigenesis and no need for transplantation are the biggest advantages of TRANsCre-

1   DIONE over stem-cell approaches. Future improvements should include combining the three

2   components of TRANsCre-DIONE into one AAV vector for easy handling and reduced cost of virus

3   production. Finally, the feasibility of TRANsCre-DIONE in the monkey brain promises immediate

4   clinical applications in various traumatic brain injuries and neurodegenerative diseases to replenish

5   dead neurons and regenerate damaged brain.

6

1   **ACKNOWLEDGMENTS**

4

5   **AUTHOR CONTRIBUTIONS**

6   H.Y.A., H-L.L, Y.H. and C.J.L. designed the study. H.Y.A and H-L.L. analyzed the data. H.Y.A. and

7   H-L.L. and C.J.L wrote the manuscript. H.Y.A. and J.P.H. cloned all the viral vectors. H.Y.A.

8   performed all surgery, IHC, analysis with mouse brain part. H.Y.A., D.W.C., Y.S.Y. and S.C.H.

9   performed and supported the animal surgery, caring, sacrificing with monkey. H.Y.L. and H-L.L.

10   performed all animal surgery behavioral tests, and analysis with SCI mouse model. H.Y.A., J.M.L.,

11   J.S.W. and J.K.L. performed slice electrophysiology. M.G.P. designed the schematic figures. All

12   authors contributed to discussion of the results.

13

14   **DECLARATION OF INTERESTS**

15   The authors declare no competing interests.

16

1 **Figure 1. The genetic strategy of transdifferentiation in the brain of a mouse and non-**

2 **human primate.**

3 (A) Experimental protocol for induction of reactiveness by virus injection and the

4 coordination of the surgery in the striatum of the mouse (left), cynomolgus monkey (middle),

5 and the mouse spinal cord (right). Unilateral injection was performed in striatum of mice (AP:

6 +0.5, ML: 1.85, DV: -3.00) and monkey (AP: +1.8, ML: 12.00, DV: -5.00). Injury was given

7 at the level of Thoracic 10 of mouse spinal cord with self-closing forceps. Virus was injected

8 into two point beside the lesion site 2 weeks after the injury. Mice were sacrificed post-

9 injection (PI) 3 weeks. Monkeys were sacrificed PI 4weeks. SCI mice were sacrificed post-

10 injury 8weeks (PI 6 weeks).

11 (B) Lcn2 (red, left panel) and iNOS (red, right panel) expression and co-localization with

12 GFAP (green, both) in the injured striatum (Str.) of mouse and monkey and mouse SCI.

13 (Arrowhead: co-localization of GFAP and Lcn2, or GFAP and iNOS). Scale bar= 20 μm

14 (mouse Str. and mouse SCI), 50 μm (monkey Str.).

15 (C) TRANsCre-DIONE, the strategy for transdifferentiation by expression of *Neurog2*

16 selectively in reactive astrocytes of mouse brain (upper) and monkey brain (lower).

17

18 **Figure 2. Transdifferentiation of reactive astrocytes into functional neurons in the**

19 **mouse brain.**

20 (A) A mixture of 3 viruses (TRANsCre-DIONE, 2μl of mixture) was injected into the

21 striatum (AP: +0.5, ML: +1.85, DV: -3.0; bilaterally). The mice were sacrificed PI 3 weeks

22 for immunohistochemistry (IHC) and *ex vivo* patch-clamp recording.

23 (B) Colocalization of GFAP (red, middle column) and NeuN (red, right column) with GFP

24 fluorescence (green, left column) in Ctrl (upper) and Neurog2 (lower) group. Scale bar=10

25 μm (Ctrl group), 25 μm (Neurog2 group).

26 (C) Stacked bar graph showing the percentage of GFAP (blue) and NeuN (pink) positive cells

27 in GFP expressing cells (black: undefined cells). n=93 (Ctrl group), n=135 (Neurog2 group).

28 (D) Colocalization of GABA (red, middle column) and NeuN (magenta, upper) with GFP

29 fluorescence (green) in Neurog2 group. Scale bar= 5 μm.

30 (E) Stacked bar graph showing the number and percentage of GABA positive (yellow) cells

31 in NeuN positive and GFP expressing (cyan) cells. Total n=471 in Neurog2 group.

1   (F) Representative trace of passive conductance (Upper) recorded from GFP expressing cells

2   (inset, scale bar=10 μm) in the control group by voltage-clamp step protocol. Scale

3   bar=500pA, 500ms. Averaged amplitude reached to around 4000pA at 50mV. Averaged I-V

4   graph (lower) from voltage of -150mV to 50mV. N=3, n=12.

5   (G) Representative action potential firing (Upper) and the trace of spontaneous EPSCs (lower,

6   left) from GFP expressing cells (inset, scale bar= 10 μm) in the Neurog2 group. The average

7   of the number of spikes (lower, right) was increased by injected current. N=6, n=35.

8

9   **Figure 3. Transdifferentiation of reactive astrocytes into functional neurons in the**

10   **monkey's brain.**

11   (A) A mixture of 3 viruses (TRANsCre-DIONE, 25μl of the mixture) was injected into the

12   striatum (AP: +1.8, ML: +12.00, DV: -5.0; unilaterally). The monkeys were sacrificed PI 4

13   weeks for IHC.

14   (B) Colocalization of GFAP (magenta) and NeuN (red) signal in GFP-expressing cells (green)

15   in the Control group (Upper) and Neurog2 group (lower). Scale bar=50 μm (low

16   magnification), 5 μm (magnified images). Arrowhead means the colocalization of GFP and

17   GFAP in Ctrl group, or GFP and NeuN in Neurog2 group.

18   (C) Scatter plot of all GFP expressing cells in Ctrl (blue dot) and Neurog2 (pink dot) group

19   classified as GFAP and NeuN intensity. Quadrant 1(light pink); GFAP+/NeuN+ (G+/N+),

20   Quadrant 2(blue); GFAP+/NeuN- (G+/N-), Quadrant 3(light blue); GFAP-/NeuN- (G-/N-),

21   Quadrant 4(pink); GFAP-/NeuN+(G-/N+) (Reference lines are drawn for dividing + or - at

22   1K of both intensities.). n=98 (Ctrl group), n=224 (Neurog2 group).

23   (D) Stacked bar graph of the percentage of G+/N-, G-/N-, G+/N+ and G-/N+ in Ctrl and

24   Neurog2 groups.

25   (E) Comparison of NeuN and GFAP intensity of GFP-expressing cells in Ctrl group.

26   Unpaired student t-test (n.s.=p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). n=98

27   (Ctrl group).

28   (F) Comparison of NeuN and GFAP intensity of GFP+ cells in Neurog2 group. Unpaired

29   student t-test. n=224 (Neurog2 group).

30   (G) Comparison of NeuN intensity of GFP+ cells in Ctrl and Neurog2 group. Unpaired

31   student t-test. n=98 (Ctrl group), n=224 (Neurog2 group).

23

1   (H) Comparison of GFAP intensity of GFP+ cells in the Ctrl and Neurog2 group. Unpaired

2   student t-test. n=98 (Ctrl group), n=224 (Neurog2 group).

3

4   **Figure 4. Transdifferentiation of scar-forming reactive astrocytes into functional**

5   **neurons in the spinal cord injury mouse model.**

6   (A) A mixture of 3 viruses (TRANsCre-DIONE, 1μl of mixture) was injected into the spinal

7   cord. Basso Mouse Scale (BMS) score was measured in every week from the first week of

8   the injury to the last week. SCI mice were sacrificed at 8 weeks after injury (PI 6 weeks) for

9   IHC and *ex vivo* patch-clamp recording.

10   (B) Schematic diagram of the protocol for setting the SCI model and virus injection in the

11   spinal cord. The SCI mouse model was set by forceps compressing protocol (compression for

12   3 sec, at Thoracic10). A mixture of 3 viruses (TRANsCre-DIONE, 1μl of mixture, upper and

13   lower of 1mm of the injury site) was injected into the spinal cord 2 weeks after injury.

14   (C) BMS scores of sham, SCI/Neurog2, SCI/Ctrl and SCI/PBS groups. BMS score was

15   measured in every week for following the functional recovery of the SCI model. (magenta;

16   Sham group, pink; SCI/Neurog2 group, blue; SCI/Ctrl group, green; SCI/PBS group).

17   Dunnett's multiple comparison test, with individual variances computed for each comparison

18   (#p<0.05). n=10 (sham group), 11 (SCI/Neurog2 group), 10 (SCI/Ctrl group), 10 (SCI/PBS

19   group).

20   (D) Action potential firing was in GFP-expressing cell (inset, scale bar=10 μm) in Neurog2

21   group. Scale bar= 20mV, 200ms.

22   (E) Large sodium channel current was shown in voltage-clamp recording from GFP-

23   expressing cell in the Neurog2 group. Scale bar= 1nA, 5ms.

24   (F) Spontaneous EPSCs from GFP-expressing cell in the Neurog2 group. Scale bar= 10pA,

25   10sec (upper); 10pA, 1sec (enlarged trace).

26

27   **Figure 5. Tissue recovery in SCI via transdifferentiation of scar-forming reactive**

28   **astrocytes into neurons.**

29   (A) Eriochrome Cyanine (EC) staining for myelin staining in cross and longitudinal sections

30   in sham, SCI/PBS, SCI/Ctrl and SCI/Neurog2 groups. (Black dot line; injury site, green dot

31   line; injection site). Scale bar= 500 μm (cross section), 1mm (longitudinal section).

1 (B) Scattered bar graph showing the area of gray matter (left), myelinated area (middle), and

2 total area (right) in sham (magenta), SCI/PBS (green), SCI/Ctrl (blue), SCI/Neurog2 (pink)

3 groups (Each value was normalized by sham group). Unpaired non-parametric one-way

4 ANOVA with Kruskal-Wallis test. n= 10 (sham group), 8 (SCI/ PBS group), 19 (SCI/Ctrl

5 group), 13 (SCI/Neurog2 group).

6 (C) MAP2 staining of longitudinal sections of Sham, SCI/PBS, SCI/Ctrl, and SCI/Neurog2

7 groups. (Scale bar= 500µm, 8 weeks)

8

9 **Figure 6. Transdifferentiation of reactive astrocytes into motor neurons in SCI.**

10 (A) Colocalization of GFAP (magenta) and MAP2 (red) with GFP fluorescence (green) in

11 sham, SCI/PBS, SCI/Ctrl and SCI/Neurog2 groups. Scale bar=20 µm.

12 (B) Colocalization of GFAP (magenta), NeuN (gray) and Isl1 (red) with GFP fluorescence

13 (green) in sham, SCI/PBS, SCI/Ctrl and SCI/Neurog2 groups. Scale bar=20 µm.

14 (C) Scattered bar graph showing comparison of MAP2 intensity in the total area. Multiple

15 comparison for unpaired non-parametric one-way ANOVA with Kruskal-Wallis test. n=9

16 (sham group), 7 (SCI/PBS group), 11 (SCI/Ctrl group), 14 (SCI/Neurog2 group).

17 (D) Scattered bar graph showing comparison of MAP2 intensity in GFP-expressing cells in

18 SCI/Ctrl and SCI/Neurog2 groups. Unpaired non-parametric t-test with Mann-Whitney test.

19 n=11 (SCI/Ctrl group), 14 (SCI/Neurog2 group).

20 (E) Stacked bar graph showing the proportion of GFAP (blue) or MAP2 (pink) positive cells

21 in GFP expressing cells. (Undefined: black).

22 (F) Stacked bar graph showing the proportion of GFAP and NeuN positive or negative cells

23 in GFP expressing cells. G+/N- (blue, quadrant 2 of Figure S4C) , G-/N- (light blue, quadrant

24 3 of Figure S4C), G+/N+ (light pink, quadrant 1 of Figure S4C)   and G-/N+ (pink, quadrant

25 4 of Figure S4C). n=102 in SCI/Ctrl, n=77 in SCI/Neurog2 group.

26 (G) Scattered bar graph showing comparison of GFAP intensity in the total area. Multiple

27 comparison for unpaired non-parametric one-way ANOVA with Kruskal-Wallis test. n=10

28 (sham group), 8 (SCI/PBS group), 18 (SCI/Ctrl group), 24 (SCI/Neurog2 group).

29 (H) Scattered bar graph showing comparison of NeuN intensity in the total area. Multiple

30 comparison for unpaired non-parametric one-way ANOVA with Kruskal-Wallis test. n=4

31 (sham group), 4 (SCI/PBS group), 13 (SCI/Ctrl group), 6 (SCI/Neurog2 group).

1   (I) Scattered bar graph showing comparison of NeuN intensity in GFP-expressing cells in

2   SCI/Ctrl and SCI/Neurog2 groups. Unpaired non-parametric t-test with Mann-Whitney test.

3   n=66 (SCI/Ctrl group), 65 (SCI/Neurog2 group).

4   (J) Scattered bar graph showing comparison of Isl1 intensity in the total area. Multiple

5   comparison for unpaired non-parametric one-way ANOVA with Kruskal-Wallis test. n=20

6   (sham group), 4 (SCI/PBS group), 14 (SCI/Ctrl group), 9 (SCI/Neurog2 group).

7   (K) Scattered bar graph showing comparison of Isl1 intensity in GFP-expressing cells in

8   SCI/Ctrl and SCI/Neurog2 groups. Unpaired non-parametric t-test with Mann-Whitney test.

9   n=11 (SCI/Ctrl group), 6 (SCI/Neurog2 group).

10   (L) Scattered bar graph showing comparison of GFP-expressing cells in Isl1-positive cells in

11   SCI/Ctrl and SCI/Neurog2 groups. Unpaired non-parametric t-test with Mann-Whitney test.

12   n=7 (SCI/Ctrl group), 6 (SCI/Neurog2 group).

13

14   **Figure 7. Transdifferentiated neurons are mostly originated from non-proliferating cells.**

15   (A) Colocalization of BrdU (red, treated for 1week from 7 weeks after injury) in GFP-

16   expressing cells (green) with cell markers (magenta; GFAP, upper; NeuN, middle; MBP,

17   lower) in SCI/Ctrl and SCI/Neurog2 groups. Scale bar=20 μm.

18   (B) Timeline of treating BrdU and IHC after sacrificing in SCI mice.

19   (C) Scattered bar graph showing comparison of percentage of BrdU-positive cells in GFP+,

20   GFAP+/GFP+ and GFP- cells in SCI/Ctrl and SCI/Neurog2 groups. n=7 (SCI/Ctrl group), 17

21   (SCI/Neurog2 group).

22   (D) Scattered bar graph showing comparison of percentage of BrdU-positive cells in GFP+,

23   NeuN+/GFP+ and GFP- cells in SCI/Ctrl and SCI/Neurog2 groups. n=7 (SCI/Ctrl group), 17

24   (SCI/Neurog2 group).

25   (E) Scattered bar graph showing comparison of percentage of BrdU-positive cells in GFP+,

26   MBP+/GFP+ and GFP- cells in SCI/Ctrl and SCI/Neurog2 groups. n=7 (SCI/Ctrl group), 17

27   (SCI/Neurog2 group).

28

29   **Table 1. Proportion of non-transdifferentiated (GFP-) proliferative (BrdU+) astrocytes**

30   **(GFAP+), neurons (NeuN+) and oligodendrocytes (MBP+)**

31

1 **METHOD & METARIALS**

2 **Animals**

3 To differentiate of reactive astrocytes into neurons directly in the brain, 7 to 10-week-old C57BL/6J
4 mice (DBL; Daehan Bio Link, Korea) were used for immunohistochemistry and electrophysiology
5 experiments. Mice were housed in an animal facility permitted by the Association for Assessment and
6 Accreditation of Laboratory Animal Care (AAALAC). All animals were maintained in a vivarium
7 with light/dark cycle (8:00 AM~8:00 PM). Animal care and handling were performed according to the
8 directives of the Animal Care and Use Committee and institutional guidelines of KIST (Seoul, Korea).
9 Animals were randomly used for experiments.

10 Three- to 4-year old cynomolgus monkeys (*Macaca fascicularis*, 2 males) were purchased from
11 NafoVanny (Dong Nai Province, Vietnam), and they were 4.1 and 3.9 kg on the dosing day. The
12 monkeys were housed individually in a stainless-steel cage (543 mm width x 715 mm depth x 818
13 mm height) and acclimatized in the study room after a 30-day quarantine period. Throughout the
14 study period, supplements, toys, and stainless-steel mirrors were supplied for environmental
15 enrichment. The room conditions were automatically controlled based on standard operating
16 procedures (a temperature of 20 - 29 °C, relative humidity of 30 - 70 %, a lighting cycle of 12 hours
17 dark/12 hours light at 300 - 700 lux and 10 - 20 air changes per hour). Filtered, ultraviolet light-irradiated
18 municipal tap water was allowed ad libitum and 120 g of commercial monkey chow (Certified Primate
19 Diet #5048, PMI Nutrition International, USA) was provided daily. The animals were identified using
20 body tattoos and cage cards. This study was performed in facilities approved by the Association for
21 Assessment and Accreditation of Laboratory Animal Care International. All procedures were
22 approved by the Institutional Animal Care and Use Committee of the Korea Institute of Toxicology.

23 **DNA Cloning and virus packaging**

24 cDNAs encoding for full-length *Lcn2* (GenBank accession no. NM_008491.1) and *Neurog2*
25 (NM_008430) were obtained by using an RT–PCR based cloning from mouse brain. *iNOS* promoter
26 (NM_000625, Product ID: HPRM30585) was purchased from Genecopoeia. GFAP-Ccre, GFAP-Ncre
27 vectors were kindly provided by Dr. Rolf Sprengel (Max Planck Institute for Medical Research).
28 pAAV-GFAP::Ccre, pAAV-GFAP::Ncre, pAAV-Lcn2::Ncre, pAAV-iNOS::Ncre, pAAV-EF1α::DIO-
29 Neurog2-IRES-GFP, pAAV-EF1α::DIO-GFP were packaged into AAV.

30 **Astrocytes primary culture**

31 Primary cultured astrocytes were electroporated at 4 DIV with a mixture of 3 plasmids (pAAV-EF1α-

27

1   df-Ngn2-IRES-GFP, pAAV-Lcn2-Ncre, pAAV-GFAP-Ccre, 1:1:1, 5μg each), astrocyte media was

2   changed to neuronal media 8 days after gene transfection. Astrocytes media contains 10% HI Horse

3   serum (Gibco, 26050-088), 10% HI Fetal Bovine Serum (Gibco, 10082-147), 1% Penicillin-

4   Streptomycin (Gibco, 15140-122) in Dulbecco Modified Eagle Medium (DMEM, Corning, 10-013-

5   CVR), neuronal media inducing neuronal differentiation includes 2% B27 (Invitrogen, 17504-044), 2%

6   Glutamax (Gibco, 35050-061) in F-12 media (Gibco, 11765-054).

7   **Stereotaxic surgery in Brain**

8   *Mouse*

9   7-10 -week-old 57/BL6 mice were used. Mice (8–10 weeks old) were anesthetized by intraperitoneal

10   injection of 2% avertin (20 µl g − 1) and placed into stereotaxic frames. AAV (titer: 1.5×10^{12} GC)

11   was loaded into a 22G Hamilton syringe and injected bilaterally into the mouse striatum region (−0.5

12   mm AP, ± 1.85 mm ML, −3.0 mm DV from the dura) at a rate of 0.2 μl min − 1 (total 2 μl) with a 25

13   μl syringe using a syringe pump (KD Scientific, Holliston, MA, USA).

14   *Monkey*

15   Animals (age 2-6 years) were anesthetized with approximately 8 - 10 mg/kg of zoletil 50 (Virbac

16   Korea) 30 min before clamped to the stereotaxic instrument (David Kopf instrument, model 1404).

17   Total 25 uL virus was injected using the Hamilton syringe and infusion pump at a speed of 2.5 uL per

18   minutes. After surgery, monkeys were prescribed 20 mg/kg of Cephalosporin-C twice per day for 5

19   days, 2 mg/kg of Ketoprofen once a day for 3 days and 1 mg/kg of Prednisolone acetate once a day

20   for 5 days. To prevent infection following surgery, surgical sites were disinfected with Betadine for 5

21   days. A mixture of AAV (2/5)-iNOS-Ccre, AAV (2/5)-GFAP-Ncre and AAV (2/5)-DF-GFP and a

22   mixture of AAV (2/5)-iNOS-Ccre, AAV (2/5)-GFAP-Ncre and AAV (2/5)-DF-NGN2-IRES-GFP were

23   injected in the putamen (AP +0.9, ML +09-1.1, DV-2.7 from bregma).

24   **Establishment of Spinal cord injury (SCI) model and AAV injection**

25   For the establishment of SCI model, *C57BL/6* was used (20g ± 2g; OrientBio, Kyungki-do, Korea),

26   housed in an animal facility permitted by the Association for Assessment and Accreditation of

27   Laboratory Animal Care (AAALAC). All animals were anesthetized with ketamine (100mg/kg; Yuhan,

28   Seoul, Republic of Korea), Rompun (10mg/kg; Bayer Korea, Seoul, Republic of Korea) and isotropy

29   100 (1 to 3%, Troikaa Pharmaceuticals Ltd, Gujarat, India). Laminectomy was performed at thoracic

30   number 10 to expose the spinal cord. The spinal cord was compressed for 3s by self-closing forceps

31   (Fine Science Tools, North Vancouver, Canada). After spinal cord injury, muscle and skin were closed

1   using 6/0 non-absorbable nylon sutures. Sham animals were operated the only laminectomy. Spinal

2   cord injured animals were randomly separated to PBS, Ctrl, and Ngn2. At 2 weeks after injury, 1 μl

3   PBS and AAV were injected at two locations (1 mm proximal and distal to the injured site) using by

4   33gauge Hamilton syringe. The injection rate was constantly maintained as 0.2 μl to min. After

5   injection, the needle was kept at the injection site for additional 5 min.

6 **BrdU assay**

7   For detection of cell proliferation, BrdU (50mg/kg; Sigma-Aldrich, B5002) was administrated by

8   intraperitoneal injection. BrdU was injected daily for 7 days from 1 week and 7 weeks after injury.

9   BrdU injected mice were sacrificed at the last day of BrdU injection. The concentration of BrdU

10   solution was 10 mg/ml in 0.9% saline and filtrated before injected to the mouse. BrdU was detected

11   by immunohistochemistry using the mouse anti-BrdU antibody (Thermo Fisher, ZBU30; 1:2000).

12 **Behavioral test**

13   For confirmation of locomotor recovery, the behavioral test was performed every week from 1 week

14   to 7 weeks after injury. The Basso Mouse Scale (BMS) score was used to quantify of hind limb

15   movement during open field locomotion. The BMS score is separated as 0 to 9 scores. The 0 score

16   means complete paralysis and 9 score means normal locomotion.

17 **Tissue sample preparation for Eriochrome Cyanine (EC) staining and Immunohistochemistry.**

18   For isolation of spinal cord, animals were sacrificed at 3 weeks and 8 weeks after injury. Blood was

19   completely removed by saline perfusion and fixed by 4% paraformaldehyde (PFA, Duksan, Ansan,

20   Korea). The isolated tissues were fixed in 4% PFA for overnight and transferred to 30% Sucrose for

21   dehydration at 4°C. Dehydrated tissues were embedded in optimal cutting temperature compound

22   (Sakura Finetek, Torrance, CA, USA), frozen at -80°C, and cut into a thickness of 20 □m by cryostat.

23 **Eriochrome Cyanine (EC) staining**

24   The sectioned tissues were dried on room temperature (RT) for 2 h and immersed in acetone for 5 min.

25   After immersion, tissues were incubated at RT for 10 min and stained by EC solution (MERCK,

26   Kenilworth, NJ, USA) at RT for 30 min. The stained tissues were rinsed by running water and 5%

27   iron alum (Sigma-Aldrich, F3629) until observing the gray matter. Tissues were differentiated by

28   borax-ferricyanide solution (Borax, Sigma-Aldrich, 71997; Potassium ferricyanide, Sigma-Aldrich,

29   702587) and dehydrated by graded ethanol solutions of 70%, 90%, and 100%. After all process,

30   tissues were mounted by permanent mounting medium (Fisher Scientific, Hampton, NH, USA) and

31   observed by the light microscope (DM 2500, Leica, Wetzlar, Germany).

1 **Immunohistochemistry**

2 *Immunohistochemistry in Brain*

3 Animals were euthanized upon completion of the treatment period with an overdose of thiopental

4 sodium administered intravenously the bled by blood collection via posterior vena cava. They were

5 fasted over 16 hours before the necropsy. The animals were examined carefully for external

6 abnormalities. The abdominal, thoracic and cranial cavities were examined for abnormalities and the

7 brain then removed and examined. Adult mice were deeply anesthetized with 2% avertin (20 µg/g)

8 and perfused with 0.1M PBS (Phosphate buffered saline) followed by ice cold 4 % PFA

9 (paraformaldehyde). Excised brains were post-fixed overnight in 4 % PFA at 4 °C and immersed in 30%

10 sucrose for 24 hrs for cryo-protection. The 30-50 µm coronal sections were prepared with cryo-stat

11 microtome (HM525, Thermo Fisher Scientific). Sections with were rinsed in PBS three times and

12 incubated 1 hr at RT with blocking solution (0.3% Triton-X, 2 % normal serum in 0.1 M PBS).

13 Sections were incubated overnight in a mixture of the primary antibodies with blocking solution at

14 4 °C on shaker. After washing three times in PBS, sections were incubated with corresponding

15 secondary antibodies for two hours and then rinsed three times with PBS. If needed, DAPI staining

16 was added during second wash step. (Pierce, 1:3000) After being dried, stained tissues were mounted

17 with an anti-fade mounting medium (Dako). A series of fluorescence images were obtained with a

18 confocal microscope (Nikon, A1R) and images were processed for later analysis using ImageJ

19 program imaging software.

20 *Immunohistochemistry in Spinal Cord*

21 The tissue sections were washed three times by 0.3% Tween 20 (Sigma-Aldrich, P1379) in PBS at RT

22 for 5 min each and blocked by 10% normal donkey serum (Jackson ImmunoResearch, West Grove,

23 PA) in PBS containing 0.3% Triton X-100 (Sigma-Aldrich, X100) at RT for 1 h. After then, primary

24 antibodies were treated such as goat anti-GFP (Abcam, Cambridge, UK, ab6662, 1:1000), chicken

25 anti-GFAP (Abcam, ab4674, 1:2000), chicken anti-MBP (Abcam, ab134018, 1:400), rabbit anti-

26 MAP2 (Abcam, ab32454, 1:1000), rabbit anti-NeuN (Abcam, ab177487, 1:800) and   mouse anti-

27 islet1(DSHB Iowa City, IA, USA, 39.4D5, 1:100) and incubated at 4°C for overnight. After three

28 times 0.3% Tween 20 washing, sections were incubated with species-specific secondary antibodies

29 conjugated with fluorescent agents such as Cy^{TM}3-donkey anti-mouse IgG (H+L) (Jackson

30 ImmunoResearch, 175-165-151; 1:600), Cy^{TM}3-donkey anti-chicken IgG (H+L) (Jackson

31 ImmunoResearch, 175-165-155; 1:600), Alexa Fluor 647-donkey anti-rabbit IgG (H+L) (Jackson

32 ImmunoResearch, 711-606-152; 1:300), Cy^{TM}5-donkey anti-chicken IgG (H+L) (Jackson

1   ImmunoResearch, 703-175-155; 1:300) and DyLight^{TM}405-donkey anti-chicken IgY$_{++}$ (H+L)

2   (Jackson ImmunoResearch, 703-476-155; 1:600) at RT for 1 h. incubated sections were washed three

3   times by 0.3% Tween 20 and stained with DAPI (DAPI; Vector Laboratories, Peterborough, UK). The

4   fluorescence was observed under a confocal laser scanning microscopy (LSM700, Carl Zeiss,

5   Oberkochen, Germany).

6   **Electrophysiology**

7   *Slice preparation*

8   Coronal mouse brain slices (300 μm) containing trigeminal caudal nucleus region were acutely

9   prepared from C57/BL6 (age 7~10 weeks). Following decapitation the brain was rapidly removed and

10   placed in cold artificial cerebrospinal fluid (ACSF) having the following composition (in mM): 130

11   NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 1 CaCl2, 3 MgCl2 and 10 glucose, pH 7.4; room

12   temperature with oxygenation (95% O2 and 5% CO2). The slices were made using an oscillating

13   tissue slicer (DSK LinearSlicer, Kyoto, Japan) at 4°C and stored in room temperature with

14   oxygenation (95% O2, 5% CO2) and prepared slices were left to recover for at least 1 hour before

15   recording.

16   *Mouse brain ex-vivo*

17   Each slice that was studied was transferred from a recovery/holding reservoir to the recording

18   chamber of a fixed-stage upright microscope (Olympus) and submerged in oxygenated ACSF that

19   was supplied to the chamber at a rate of 1.5~2 ml/min. The submerged slice was visualized either

20   directly via the microscope's optics, or indirectly via a high-resolution CCD camera system (Orca

21   Flash 2.1, Hamamatsu) that received the output of a CCD camera attached to the microscope's video

22   port. Experiments with a holding current of more than -100 pA or in which there was a change in

23   input resistance >30% of the control were rejected. Recordings were obtained using Multiclamp 700A

24   amplifier (Molecular Devices, Sunnyvale, CA) and were filtered at 2 kHz. Current recordings under

25   ramp protocol and step were digitized at 10 kHz with DigiDATA 1550B1 (Molecular Devices,

26   Sunnyvale, CA) and analyzed using pCLAMP 10 software (Molecular Devices, Sunnyvale, CA).

27   Whole-cell recordings from GFP expressing cells were carried out with internal solution composed of

28   (mM): 120 potassium gluconate, 10 KCl, 1 MgCl2, 0.5 EGTA, 40 HEPES (pH 7.2 was adjusted with

29   KOH)

30   **Statistics**

31   Data are presented as mean ± SEM. Levels of statistical significance are indicated as follows: *P <

1   0.05, **P < 0.01, and ***P < 0.001. For full information, see statistics tables in supplementary

2   information.

3

1 **KEY RESOURCES TABLE**

2

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Chicken anti-GFAP antibody	Millipore	AB5541
Chicken anti-MAP2 antobody	abCam	ab5392
Mouse anti-NeuN antibody	Millipore	MAB377
Rabbit anti-iNOS antibody	Thermo Fisher	PA3-030A
Goat anti-Lcn2 antibody	abCam	ab2267
Rabbit anti-islet1 antibody	DSHB Iowa City	N/A
Chicken anti-MBP antibody	abCam	ab134018
Goat anti-GFP	abCam	ab6662
Mouse anti-BrdU antibody	Thermo Fisher	ZBU30
Bacterial and Virus Strains		
AAV-Lcn2-Ncre	KIST virus facility	N/A
AAV-GFAP-Ccre	KIST virus facility	N/A
AAV-iNOS-Ccre	KIST virus facility	N/A
AAV-GFAP-Ncre	KIST virus facility	N/A
AAV-EF1α-df-Ngn2-IRES-EGFP	KIST virus facility	N/A
AAV-EF1α-df-GFP	KIST virus facility	N/A
Chemicals, Peptides, and Recombinant Proteins		
Dulbecco Modified Eagle Medium (DMEM)	Corning	10-013-CVR
Penicillin-Streptomycin	Gibco	15140-122
HI Fetal Bovine Serum	Gibco	10082-147
HI Horse serum	Gibco	26050-088
B27	Invitrogen	17504-044
Glutamax	Gibco	35050-061

| F-12 media	Gibco	11765-054
BrdU	Sigma-Aldrich	B5002
Iron alum	Sigma-Aldrich	F3629
Borax	Sigma-Aldrich	71997
Potassium ferricyanide	Sigma-Aldrich	702587
Recombinant DNA		
pAAV-Lcn2-Ncre		
pAAV-GFAP-Ccre		
pAAV-iNOS-Ccre		
pAAV-GFAP-Ncre		
pAAV-EF1α-df-Ngn2-IRES-EGFP		
pAAV-EF1α-df-GFP		
Software and Algorithms		
GraphPad Prism 7	GraphPad software	https://www.graphpad.com/scientific-software/prism/; RRID: SCR_015807
ImageJ	National Institutes of Health	https://imagej.nih.gov/ij/; RRID: SCR_003070
Other		
Neon Transfection System		MPK5000
Neon™ Transfection System Kit		MPK10025

1

2

3

4

Reference

Abad, M., Mosteiro, L., Pantoja, C., Canamero, M., Rayon, T., Ors, I., Grana, O., Megias, D., Dominguez, O., Martinez, D., *et al.* (2013). Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature *502*, 340-345.

Ahuja, C.S., Nori, S., Tetreault, L., Wilson, J., Kwon, B., Harrop, J., Choi, D., and Fehlings, M.G. (2017). Traumatic Spinal Cord Injury-Repair and Regeneration. Neurosurgery *80*, S9-S22.

Alizadeh, A., Dyck, S.M., and Karimi-Abdolrezaee, S. (2019). Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front Neurol *10*, 282.

An, H., Cho, D.W., Lee, S.E., Yang, Y.S., Han, S.C., and Lee, C.J. (2016). Differential Cellular Tropism of Lentivirus and Adeno-Associated Virus in the Brain of Cynomolgus Monkey. Exp Neurobiol *25*, 48-54.

Anderson, M.A., Burda, J.E., Ren, Y., Ao, Y., O'Shea, T.M., Kawaguchi, R., Coppola, G., Khakh, B.S., Deming, T.J., and Sofroniew, M.V. (2016). Astrocyte scar formation aids central nervous system axon regeneration. Nature *532*, 195-200.

Assinck, P., Duncan, G.J., Hilton, B.J., Plemel, J.R., and Tetzlaff, W. (2017). Cell transplantation therapy for spinal cord injury. Nat Neurosci *20*, 637-647.

Barres, B.A. (1991). New roles for glia. J Neurosci *11*, 3685-3694.

Berninger, B., Costa, M.R., Koch, U., Schroeder, T., Sutor, B., Grothe, B., and Gotz, M. (2007). Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. J Neurosci *27*, 8654-8664.

Bi, F., Huang, C., Tong, J., Qiu, G., Huang, B., Wu, Q., Li, F., Xu, Z., Bowser, R., Xia, X.G., *et al.* (2013). Reactive astrocytes secrete lcn2 to promote neuron death. Proc Natl Acad Sci U S A *110*, 4069-4074.

Brenner, M., Kisseberth, W.C., Su, Y., Besnard, F., and Messing, A. (1994). GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci *14*, 1030-1037.

Brulet, R., Matsuda, T., Zhang, L., Miranda, C., Giacca, M., Kaspar, B.K., Nakashima, K., and Hsieh, J. (2017). NEUROD1 Instructs Neuronal Conversion in Non-Reactive Astrocytes. Stem Cell Reports *8*, 1506-1515.

Burda, J.E., and Sofroniew, M.V. (2014). Reactive gliosis and the multicellular response to CNS damage and disease. Neuron *81*, 229-248.

Cho, H.H., Cargnin, F., Kim, Y., Lee, B., Kwon, R.J., Nam, H., Shen, R., Barnes, A.P., Lee, J.W., Lee, S., *et al.* (2014). Isl1 directly controls a cholinergic neuronal identity in the developing forebrain and spinal cord by forming cell type-specific complexes. PLoS Genet *10*, e1004280.

Chun, H., An, H., Lim, J., Woo, J., Lee, J., Ryu, H., and Lee, C.J. (2018). Astrocytic proBDNF and Tonic GABA Distinguish Active versus Reactive Astrocytes in Hippocampus. Exp Neurobiol *27*, 155-170.

Chun, H., and Lee, C.J. (2018). Reactive astrocytes in Alzheimer's disease: A double-edged sword.

1   Neurosci Res *126*, 44-52.

2   Cregg, J.M., DePaul, M.A., Filous, A.R., Lang, B.T., Tran, A., and Silver, J. (2014). Functional
3   regeneration beyond the glial scar. Exp Neurol *253*, 197-207.

4   De Pitta, M., Volman, V., Berry, H., and Ben-Jacob, E. (2011). A tale of two stories: astrocyte
5   regulation of synaptic depression and facilitation. PLoS Comput Biol *7*, e1002293.

6   Guo, Z., Zhang, L., Wu, Z., Chen, Y., Wang, F., and Chen, G. (2014). In vivo direct reprogramming of
7   reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model.
8   Cell Stem Cell *14*, 188-202.

9   Heinrich, C., Blum, R., Gascon, S., Masserdotti, G., Tripathi, P., Sanchez, R., Tiedt, S., Schroeder, T.,
10   Gotz, M., and Berninger, B. (2010). Directing astroglia from the cerebral cortex into subtype
11   specific functional neurons. PLoS Biol *8*, e1000373.

12   Hirrlinger, J., Requardt, R.P., Winkler, U., Wilhelm, F., Schulze, C., and Hirrlinger, P.G. (2009a). Split-
13   CreERT2: temporal control of DNA recombination mediated by split-Cre protein fragment
14   complementation. PLoS One *4*, e8354.

15   Hirrlinger, J., Scheller, A., Hirrlinger, P.G., Kellert, B., Tang, W., Wehr, M.C., Goebbels, S., Reichenbach,
16   A., Sprengel, R., Rossner, M.J., *et al*. (2009b). Split-cre complementation indicates coincident activity
17   of different genes in vivo. PLoS One *4*, e4286.

18   Hu, X., Qin, S., Huang, X., Yuan, Y., Tan, Z., Gu, Y., Cheng, X., Wang, D., Lian, X.F., He, C., *et al*. (2019).
19   Region-Restrict Astrocytes Exhibit Heterogeneous Susceptibility to Neuronal Reprogramming. Stem
20   Cell Reports *12*, 290-304.

21   Kijima, K., Kubota, K., Hara, M., Kobayakawa, K., Yokota, K., Saito, T., Yoshizaki, S., Maeda, T., Konno,
22   D., Matsumoto, Y., *et al*. (2019). The acute phase serum zinc concentration is a reliable biomarker
23   for predicting the functional outcome after spinal cord injury. EBioMedicine *41*, 659-669.

24   Li, H., and Chen, G. (2016). In Vivo Reprogramming for CNS Repair: Regenerating Neurons from
25   Endogenous Glial Cells. Neuron *91*, 728-738.

26   Liu, M.H., Li, W., Zheng, J.J., Xu, Y.G., He, Q., and Chen, G. (2020). Differential neuronal
27   reprogramming induced by NeuroD1 from astrocytes in grey matter versus white matter. Neural
28   Regen Res *15*, 342-351.

29   Liu, M.L., Zang, T., and Zhang, C.L. (2016). Direct Lineage Reprogramming Reveals Disease-Specific
30   Phenotypes of Motor Neurons from Human ALS Patients. Cell Reports *14*, 115-128.

31   Liu, Y., Namba, T., Liu, J., Suzuki, R., Shioda, S., and Seki, T. (2010). Glial fibrillary acidic protein-
32   expressing neural progenitors give rise to immature neurons via early intermediate progenitors
33   expressing both glial fibrillary acidic protein and neuronal markers in the adult hippocampus.
34   Neuroscience *166*, 241-251.

35   Matsuda, T., Irie, T., Katsurabayashi, S., Hayashi, Y., Nagai, T., Hamazaki, N., Adefuin, A.M.D., Miura,
36   F., Ito, T., Kimura, H., *et al*. (2019). Pioneer Factor NeuroD1 Rearranges Transcriptional and
37   Epigenetic Profiles to Execute Microglia-Neuron Conversion. Neuron *101*, 472-485 e477.

Mattugini, N., Bocchi, R., Scheuss, V., Russo, G.L., Torper, O., Lao, C.L., and Gotz, M. (2019). Inducing Different Neuronal Subtypes from Astrocytes in the Injured Mouse Cerebral Cortex. Neuron *103*, 1086-1095 e1085.

Miskinyte, G., Devaraju, K., Gronning Hansen, M., Monni, E., Tornero, D., Woods, N.B., Bengzon, J., Ahlenius, H., Lindvall, O., and Kokaia, Z. (2017). Direct conversion of human fibroblasts to functional excitatory cortical neurons integrating into human neural networks. Stem Cell Res Ther *8*, 207.

Nagoshi, N., and Okano, H. (2018). iPSC-derived neural precursor cells: potential for cell transplantation therapy in spinal cord injury. Cell Mol Life Sci *75*, 989-1000.

Okada, S., Hara, M., Kobayakawa, K., Matsumoto, Y., and Nakashima, Y. (2018). Astrocyte reactivity and astrogliosis after spinal cord injury. Neurosci Res *126*, 39-43.

Park, Y.M., Chun, H., Shin, J.I., and Lee, C.J. (2018). Astrocyte Specificity and Coverage of hGFAP-CreERT2 [Tg(GFAP-Cre/ERT2)13Kdmc] Mouse Line in Various Brain Regions. Exp Neurobiol *27*, 508-525.

Roybon, L., Mastracci, T.L., Li, J., Stott, S.R., Leiter, A.B., Sussel, L., Brundin, P., and Li, J.Y. (2015). The Origin, Development and Molecular Diversity of Rodent Olfactory Bulb Glutamatergic Neurons Distinguished by Expression of Transcription Factor NeuroD1. PLoS One *10*, e0128035.

Russo, A., Gianni, L., Kinsella, T.J., Klecker, R.W., Jr., Jenkins, J., Rowland, J., Glatstein, E., Mitchell, J.B., Collins, J., and Myers, C. (1984). Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Res *44*, 1702-1705.

Seo, S., Lim, J.W., Yellajoshyula, D., Chang, L.W., and Kroll, K.L. (2007). Neurogenin and NeuroD direct transcriptional targets and their regulatory enhancers. EMBO J *26*, 5093-5108.

Su, Z., Niu, W., Liu, M.L., Zou, Y., and Zhang, C.L. (2014). In vivo conversion of astrocytes to neurons in the injured adult spinal cord. Nat Commun *5*, 3338.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell *131*, 861-872.

Tang, Y., Liu, M.L., Zang, T., and Zhang, C.L. (2017). Direct Reprogramming Rather than iPSC-Based Reprogramming Maintains Aging Hallmarks in Human Motor Neurons. Front Mol Neurosci *10*.

Tepper, J.M., Tecuapetla, F., Koos, T., and Ibanez-Sandoval, O. (2010). Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat *4*, 150.

Tronche, F., Casanova, E., Turiault, M., Sahly, I., and Kellendonk, C. (2002). When reverse genetics meets physiology: the use of site-specific recombinases in mice. FEBS Lett *529*, 116-121.

Victor, M.B., Richner, M., Hermanstyne, T.O., Ransdell, J.L., Sobieski, C., Deng, P.Y., Klyachko, V.A., Nerbonne, J.M., and Yoo, A.S. (2014). Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron *84*, 311-323.

Walsh, K.A., Megyesi, J.F., Wilson, J.X., Crukley, J., Laubach, V.E., and Hammond, R.R. (2004).

Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation *1*, 8.

Wang, L.L., Su, Z., Tai, W., Zou, Y., Xu, X.M., and Zhang, C.L. (2016). The p53 Pathway Controls SOX2-Mediated Reprogramming in the Adult Mouse Spinal Cord. Cell Rep *17*, 891-903.

Wang, X., Xu, Z., Tian, Z., Zhang, X., Xu, D., Li, Q., Zhang, J., and Wang, T. (2017). The EF-1alpha promoter maintains high-level transgene expression from episomal vectors in transfected CHO-K1 cells. J Cell Mol Med *21*, 3044-3054.

Wu, Z. (2020). Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease. Nat Comm *11*.

Wu, Z., Parry, M., Hou, X.Y., Liu, M.H., Wang, H., Cain, R., Pei, Z.F., Chen, Y.C., Guo, Z.Y., Abhijeet, S., *et al.* (2020). Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease. Nat Commun *11*, 1105.

Xu, J., Du, Y., and Deng, H. (2015). Direct lineage reprogramming: strategies, mechanisms, and applications. Cell Stem Cell *16*, 119-134.

Yin, J.C., Zhang, L., Ma, N.X., Wang, Y., Lee, G., Hou, X.Y., Lei, Z.F., Zhang, F.Y., Dong, F.P., Wu, G.Y., *et al.* (2019). Chemical Conversion of Human Fetal Astrocytes into Neurons through Modulation of Multiple Signaling Pathways. Stem Cell Reports *12*, 488-501.

Zhao, M.L., Liu, J.S., He, D., Dickson, D.W., and Lee, S.C. (1998). Inducible nitric oxide synthase expression is selectively induced in astrocytes isolated from adult human brain. Brain Res *813*, 402-405.

Zhou, H., Su, J., Hu, X., Zhou, C., Li, H., Chen, Z., Xiao, Q., Wang, B., Wu, W., Sun, Y., *et al.* (2020). Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. Cell *181*, 590-603 e516.

Figure 1

A

**Mouse Striatum**
(C57BL/6)

Contra | Ipsi

AP: +0.5
ML: +1.85
DV: -3.00

Virus Injection
(Injury)   Sacrifice

0w   PI 3w

Monkey Striatum
(Cynomolgus)

Contra | Ipsi

AP: +1.8
ML: +12.00
DV: -5.00

Virus Injection
(Injury)   Sacrifice

0w   PI 4w

Mouse Spinal cord (T10)

Spinal   Virus
Cord Injury Injection   Sacrifice

0w   2w   8w

B

C

TRANsCre-DIONE

For mouse

- Lcn2 - Ncre — X — GFAP - Ccre -

Lcn2+ cells / GFAP+ cells

AAV-Lcn2-Ncre
AAV-GFAP-Ccre
AAV-EF1α-df-Neurog2-IRES-GFP
Double floxed

Reactive astrocyte
(GFAP + & Lcn2+)

Normal astrocyte
(GFAP+)

For monkey

- GFAP - Ncre — X — iNOS - Ccre -

GFAP+ cells / iNOS+ cells

AAV-GFAP-Ncre
AAV-iNOS-Ccre
AAV-EF1α-df-Neurog2-IRES-GFP
Double floxed

Reactive astrocyte
(GFAP + & iNOS+)

Normal astrocyte
(GFAP+)

Figure 2

A TRANsCre-DIONE

Ctrl
- AAV-EF1α-df-GFP
- AAV-Lcn2-Ncre
- AAV-GFAP-Ccre

Ngn2
- AAV-EF1α-df-Neurog2-IRES-GFP
- AAV-Lcn2-Ncre
- AAV-GFAP-Ccre

AP: +0.5
ML: +1.85
DV: -3.00

Virus Injection (Injury)   Slice Patch   IHC

0w   PI 3w

B

GFP   GFP+GFAP   GFP+NeuN

Ctrl

Neurog2

10μm

25μm

C

% of GFAP+ or NeuN+ Cells in GFP+ Cells

GFAP
NeuN
Unknown

Ctrl (n=93)   Neurog2 (n=135)

D

Neurog2

GFP   5μm   NeuN   GFP+NeuN

GABA   MERGE

GFP+GABA

E

GABA+ in GFP+/NeuN+ (%)

GFP+NeuN
GABA+ GFP+NeuN

n=471

F Ctrl Group (Passive Conductance)

10μm

500pA
500ms   0pA

n=12, N=3

(pA) 6000
4000
2000
-150   -100   -50   50 (mV)
-2000
-4000

G Neurog2 Group (AP Firing)

10μm

20mV
500ms

n=35, N=6

Number of Spike (n)
30
20
10
0   20   40   60   80   100   120
Injected Current (pA)

Figure 3

A   **TRANsCre-DIONE**

Ctrl
- AAV-EF1α-df-GFP
- AAV-GFAP-Ncre
- AAV-iNOS-Ccre

Ngn2
- AAV-EF1α-df-Neurog2-IRES-GFP
- AAV-GFAP-Ncre
- AAV-iNOS-Ccre

AP: +1.8
ML: +12.00
DV: +5.00

Virus Injection (Injury)   **Sacrifice**

0w   PI 4w

B

C

D

E Ctrl

F Neurog2

G

H

Figure 4

A **TRANsCre-DIONE**

Ctrl
- AAV-EF1α-df-GFP
- AAV-Lcn2-Ncre
- AAV-GFAP-Ccre

Ngn2
- AAV-EF1α-df-Neurog2-IRES-GFP
- AAV-Lcn2-Ncre
- AAV-GFAP-Ccre

Spinal Cord Injury (red) — **Virus Injection** (blue) — **Slice Patch** (green) **IHC** (black)

0w   2w   8w

BMS score

B

2 weeks later

C

Basso Mouse Scale (BMS)

Weeks

- Sham (10)
- SCI/Neurog2 (11)
- SCI/Ctrl (10)
- SCI/PBS (10)

D SCI/Neurog2 group

60mV

10μm

20mV
200ms

E

1nA
5ms

F

10pA
10 sec

10pA
1 sec

Figure 5

A

Sham   SCI/PBS   SCI/Ctrl   SCI/Neurog2

500μm

Injection
1mm
Injury
1mm
Injection

1mm

B

Gray Matter Area (Normalized to Sham)

**
**

1.5
1.0
0.5
0

Sham SCI/PBS SCI/Ctrl SCI/Neurog2

Myelinated Area (Normalized to Sham)

****
**

1.5
1.0
0.5
0

Sham SCI/PBS SCI/Ctrl SCI/Neurog2

Total Area (Normalized to Sham)

****
**

1.5
1.0
0.5
0

Sham SCI/PBS SCI/Ctrl SCI/Neurog2

C

Sham   SCI/PBS   SCI/Ctrl   SCI/Neurog2

500um

Figure 6

Figure 7

Table 1

		GFAP		NeuN		MBP	
		SCI/Ctrl	SCI/Neurog2	SCI/Ctrl	SCI/Neurog2	SCI/Ctrl	SCI/Neurog2
3 week	Total BrdU+	52	22	138	156	230	158
	GFP-/BrdU+/Marker+	5	1	0	7	21	19
		9.62%	4.55%	0.00%	4.49%	9.13%	12.03%
8 week	Total BrdU+	64	98	207	204	75	134
	GFP-/BrdU+/Marker+	8	10	4	20	1	16
		12.50%	10.20%	1.93%	9.80%	1.33%	11.94%